Onegene Biotechnology products

With our proprietary protein-protein conjugation technology, UniStac, we develop highly potent tri- or tetraspecific antibodies. It allows unlimited combination of different type of molecules, such as Fv fragment, ScFv, SdFv, peptide, cytokines, growth factors, or enzymes.

OGB23501 is a first-in-class tri-specific tumor microenvironment (TME) immune activator, which simultaneously targets PD-1, CTLA-4, and VEGF. We aim to develop it as a potential backbone therapy for melanoma, NSCLC, HCC, and renal carcinoma.

OGB21502 is an augmented FGF21 on a nonclinical stage that is conjugated to albumin, GLP-1, GCG, and α-cytokine. This tetra-specific, tetra-valent molecule is only 120 kDa in size, demonstrating good physical stability. This well-balanced tetra-agonist may be the ideal therapy for the treatment of fibrosis as well as NASH. OGB21502 is scheduled for IND filing in 2023.

OGB21501 is a long-acting recombinant protein of GLP-1/GIP/GCG/FGF21 generated by applying our proprietory protein conjugation platform, UniStac, and it is a tetra-specific drug for the treatment of non-alcoholic steatohepatitis (NASH). It simultaneously targets four different mechanisms that are proven to be effective in resolving hepatic inflammation and fibrosis.

Onegene Biotechnology is pioneering multi-target therapeutics to create breakthrough medicines that will transform the lives of people with complex and chronic diseases. Onegene’s proprietary platform, UniStac®, allows rapid expansion of promising combinations of the targets into a single multi-target molecule with enzyme-mediated protein-protein conjugation technology while removing time-consuming heterodimerization engineering process.